stockrow
Friday 6 November 2026
Export NCEL’s income statement to Excel — free account
NewcelX Ltd.
NCEL Healthcare Biotechnology
2.72
0.17
−5.88%
Follow NCEL
Alert me
NewcelX Ltd. (NCEL) P/E ratio
NewcelX Ltd. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NEUP Neuphoria Therapeutics Inc. compare | n/m |
| JSPR Jasper Therapeutics, Inc. compare | n/m |
| ALLR Allarity Therapeutics, Inc. compare | n/m |
| PLUR Pluri Inc. compare | n/m |
| MRKR MARKER THERAPEUTICS, INC. compare | n/m |
| VAXX Vaxxinity, Inc. compare | n/m |
| NCEL NewcelX Ltd. | n/m |
| CTXR Citius Pharmaceuticals, Inc. compare | n/m |
| ABOS Acumen Pharmaceuticals, Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)